Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: a cost-effectiveness analysis

被引：0
|
作者：
Barrington, David [1 ]
Calhoun, Cody [1 ]
Haight, Paulina [1 ]
Tubbs, Crystal [1 ]
Cohn, David [1 ]
Bixel, Kristin [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
GYNECOLOGIC ONCOLOGY | 2021年 / 162卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
56
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [31] New drug approval: Pembrolizumab plus lenvatinib in second line for patients with advanced or recurrent endometrial cancer
    De Jesus, Clara
    Rodrigues, Manuel
    BULLETIN DU CANCER, 2022, 109 (7-8) : 740 - 741
  • [32] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB plus CHEMOTHERAPY FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN JAPAN
    Akai, M.
    Moriwaki, K.
    Morimoto, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2024, 27 (06) : S69 - S69
  • [33] Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China
    Zheng, Zhiwei
    Song, Xiaobing
    Qiu, Guodong
    Xu, Siqi
    Cai, Hongfu
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (03) : 433 - 440
  • [34] Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis
    Liu, Kun
    Zhu, Youwen
    Zhou, Yangying
    Zhang, Yu
    Zhu, Hong
    GYNECOLOGIC ONCOLOGY, 2022, 166 (03) : 582 - 588
  • [35] Pembrolizumab Plus Lenvatinib Approved in Advanced Endometrial Carcinoma
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 610 - 610
  • [36] THE COST-EFFECTIVENESS OF IMMUNOTHERAPIES FOR ADVANCED OR RECURRENT ENDOMETRIAL CANCER: A SYSTEMATIC REVIEW
    Ahmadu, C.
    Coyle, S.
    Darlington, O.
    VALUE IN HEALTH, 2024, 27 (12) : S355 - S355
  • [37] A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib plus pembrolizumab
    Yanazume, Shintaro
    Kobayashi, Yusuke
    Kirita, Yukari
    Kitazono, Ikumi
    Nagata, Chikako
    Kozai, Ayumi
    Tanimoto, Akihide
    Kobayashi, Hiroaki
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2025, 51 (01)
  • [38] Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Updated results.
    Makker, Vicky
    Rasco, Drew W.
    Vogelzang, Nicholas J.
    Messing, Mark
    Brose, Marcia S.
    Cohn, Allen Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC)
    Makker, Vicky
    Taylor, Matthew H.
    Aghajanian, Carol
    Oaknin, Ana
    Mier, James
    Cohn, Allen L.
    Romeo, Margarita
    Bratos, Raquel
    Brose, Marcia S.
    Di Simone, Christopher
    Messing, Mark
    Dutta, Lea
    Ren, Min
    Schmidt, Emmett V.
    Orlowski, Robert
    McKenzie, Jodi A.
    Gillis, Kathryn
    Young, Louise
    Herraez, Antonio Casado
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 133 - 134
  • [40] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC).
    Makker, Vicky
    Taylor, Matthew H.
    Aghajanian, Carol
    Oaknin, Ana
    Mier, James
    Lee Cohn, Allen
    Romeo, Margarita
    Bratos, Raquel
    Brose, Marcia S.
    DiSimone, Christopher
    Messing, Mark
    Dutta, Lea
    Ren, Min
    Schmidt, Emmett, V
    Orlowski, Robert
    Alicia McKenzie, Jodi
    Gillis, Kathryn
    Casado Herraez, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345